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Abstract: Clostridioides difficile is the main cause of health-care-associated infectious diarrhoea. Toxins,
TcdA and TcdB, secreted by this bacterium damage colonic epithelial cells and in severe cases this
culminates in pseudomembranous colitis, toxic megacolon and death. Vaccines in human trials
have focused exclusively on the parenteral administration of toxin-based formulations. These vac-
cines promote toxin-neutralising serum antibodies but fail to confer protection from infection in
the gut. An effective route to immunise against gut pathogens and stimulate a protective mucosal
antibody response (secretory immunoglobulin A, IgA) at the infection site is the oral route. Ad-
ditionally, oral immunisation generates systemic antibodies (IgG). Using this route, two different
antigens were tested in the hamster model: The colonisation factor CD0873 and a TcdB fragment.
Animals immunised with CD0873 generated a significantly higher titre of sIgA in intestinal fluid and
IgG in serum compared to naive animals, which significantly inhibited the adherence of C. difficile to
Caco-2 cells. Following challenge with a hypervirulent isolate, the CD0873-immunised group showed
a mean increase of 80% in time to experimental endpoint compared to naïve animals. Survival and
body condition correlated with bacterial clearance and reduced pathology in the cecum. Our findings
advocate CD0873 as a promising oral vaccine candidate against C. difficile.
Keywords: mucosal immunity; sIgA; oral vaccination; Clostridioides difficile; colonisation factor
1. Introduction
Clostridioides difficile is a Gram-positive, spore-forming anaerobic bacillus found in
the intestinal tract of humans and certain animals (dogs, cats, pigs and birds) and in the
environment. Approximately 5% of healthy adults and 15–70% of infants are colonised
by C. difficile but its prevalence is much greater in hospitalised patients or nursing home
residents [1]. The incidence and severity of C. difficile infection (CDI) has increased over
the past 20 years [2] such that it is now the leading cause of hospital-acquired infection
worldwide [3]. In the US, CDI accounts for 15% of all nosocomial infections [4]. The an-
nual economic cost of CDI in the US is estimated to be $5.4 billion with $4.7 billion of
the costs incurred in healthcare settings [5]. Risk factors associated with CDI are mainly
antibiotic therapy [6] and age (over 65 years) [1], also immunosuppressive therapy, se-
vere underlying illness, recent surgery and prolonged hospitalization or nursing home
stay [7–13]. In addition, recent studies show that the incidence of community-acquired
CDI is increasing [14].
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The life cycle of C. difficile begins with the ingestion of spores from faecal–oral transmis-
sion. The spores are dormant and hardy and survive in the environment. When ingested,
spores resist the proteolytic enzymes and acidity of the stomach and enter the intestine
where they can persist [6]. Bile acids play an important role in inducing germination of
these spores into metabolically active vegetative cells [15]. When the balance of microor-
ganisms in the colon is disrupted due to antibiotics, the constitution of bile salts changes,
which promotes germination. Furthermore, the colonisation resistance barrier is reduced
giving C. difficile the opportunity to colonise the enterocytes and multiply [16]. C. difficile is
a non-invasive pathogen and its virulence is attributed to enzymes such as collagenase and
hyaluronidase and to its exotoxins, TcdA and TcdB. In the case of hypervirulent strains,
a third toxin, C. difficile transferase (CDT or binary toxin) is produced. TcdA and TcdB are
potent monoglucosyltransferases that damage the cytoskeleton of epithelial cells lining
the colon, which leads to disruption of the tight junctions, fluid secretion and neutrophil
infiltration [17].
The clinical presentation of CDI ranges from an asymptomatic carrier state to a mild
or moderate condition (abdominal pain, fever, nausea and vomiting, weakness and loss of
appetite) to life-threatening fulminant colitis. In severe cases, patients may present with
pseudomembranous colitis, toxic megacolon, perforation of the colon, and septic shock [18].
The mortality rate directly attributed to CDI is approximately 5% but mortality associated
with CDI complications reaches 15–25% and up to 34% in patients admitted to intensive
care units [19].
Antibiotics are the mainstay of therapy [20]. Metronidazole has traditionally been
the first-line drug for mild to moderate cases and vancomycin for severe and recurrent
CDI [21]. As they are broad spectrum antibiotics, they dramatically reduce the amount
of intestinal microbiota that play an important role in inhibiting germination of spores
or in directly killing C. difficile. The resulting dysbiosis leaves patients vulnerable to a
subsequent infection. A narrow-spectrum macrolide antibiotic, fidaxomicin, with compara-
ble efficacy to vancomycin against C. difficile was approved in 2011. Fidaxomicin has no
significant influence on the flora of the colon and is associated with a lower percentage
of CDI recurrence than vancomycin. Fidaxomicin and vancomycin are now the corner-
stone of CDI treatment [18,22]. Antibiotic treatments however have serious limitations.
Firstly, they predispose patients to relapse particularly in the case of hypervirulent epi-
demic 027 strains. Recurrent CDI occurs in 10–25% of patients during the first week after
completing treatment for the initial episode and increases up to 65% in patients who have
already experienced relapse more than once [20,23]. Secondly, antibiotics impose selection
pressure for the development of resistance. To minimise recurrence, faecal microbiota
transplantation (FMT) may be offered to rapidly restore the gut flora. FMT along with
withdrawal of antibiotics achieves the highest rate of prevention of recurrent CDI among
all therapeutic options to date [24–26]. However, the potential for long-term side effects of
FMT remain to be investigated.
In terms of natural protection, as high levels of antibodies against TcdA and TcdB
have been shown to correlate with the prevention of primary CDI and low rates of re-
currence [27,28], passive immunisation strategies were developed. Therapeutic benefits
have been demonstrated for Bezlotoxumab, a monoclonal antibody specific for TcdB.
However, the use of Bezlotoxumab is limited by high cost and its unavoidably transient
action [29].
The only solution for long-term protection from primary CDI as well as recurrence is to
actively immunise. Intra-muscular (i.m.) vaccines based on inactivated forms of TcdA and
TcdB have been developed by Sanofi Pasteur and Pfizer, and on defined toxin fragments
by Valneva. These formulations have proved safe and immunogenic, with high titres of
toxin-neutralising serum antibodies detected. However, Sanofi Pasteur withdrew their
vaccine from a phase III trial when data showed it failed to protect from CDI. Valneva has
suspended their trial and results are pending for Pfizer’s phase III trial.
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The majority of licensed vaccines for infectious diseases are administered parenterally
either by subcutaneous or i.m. injection. The resulting immune response is generally
limited to systemic humoral immunity with some cellular immunity, and only weak
protection is generated at mucosal surfaces [30,31]. In contrast, vaccination at mucosal
surfaces induces sIgA and cell-mediated immune responses, while still producing systemic
IgG [32–35]. To immunise against gut pathogens, the most direct route to target the small
intestine and generate local protective immune responses is the oral route, mimicking
the natural infection route. Indeed, several oral vaccines have been licensed and have
proven to be highly effective including those directed against typhoid, cholera, polio and
rotavirus [31].
In order to investigate the oral route to immunise against C. difficile, a pilot study
was conducted in hamsters. Enteric capsules were used to deliver two recombinant
antigens to the small intestine. The hamster is a clinically relevant model for CDI as
it manifests the full course of infection seen in humans. Moreover, being particularly
susceptible to CDI, the hamster is a lethality model and thus an effective indicator of
protective immunity [36]. One of the antigens chosen was the C. difficile colonisation
factor CD0873. Following the initial identification of CD0873 as an immunoreactive protein
in human infection [37], further studies in mice confirmed CD0873 to be an immunogenic
surface-exposed lipoprotein that functions in adhesion of C. difficile to epithelial cells [38,39].
Another antigen (fragment) we chose was the terminal 514 amino acids of TcdB. Several
studies have investigated the immunogenicity of individual portions of the two toxins given
their large size. For both TcdA and TcdB, the region that is crucial for eliciting neutralising
antibodies is the receptor binding domain (RBD) located at the C-terminus [40–45]. In short,
the findings of our study advocate CD8730 as a promising vaccine candidate that when
delivered orally stimulates a potent mucosal intestinal response with some protective
efficacy afforded against CDI.
2. Materials and Methods
2.1. Bacterial Strains
Escherichia coli strains were purchased from New England Biolabs (NEB), Hitchin, UK;
“NEB® 5-alpha competent E. coli” was used for cloning purposes and “T7 Express compe-
tent E. coli” was used for recombinant protein expression. Strains were cultured aerobically
in Luria Bertani (LB) broth with shaking or on LB agar (Fisher Bioreagents, Loughbor-
ough, UK) at 37 ◦C unless stated otherwise. Where appropriate, ampicillin was added to a
final concentration of 100 µg/mL.
Clostridioides difficile strain 630 (PCR ribotype 012) was kindly provided by Peter Mul-
lany, UCL. Strain R20291ermB was previously generated in which ermB conferring resistance
to erythromycin was integrated into the genome of epidemic strain R20291 (PCR ribo-
type 027) [46]). Strains were cultured in Brain Heart Infusion medium (Oxoid) supple-
mented with 5 µg/mL yeast extract and 0.1% w/v L-cysteine (BHIS) containing selec-
tive supplements; 250 µg/mL D-cycloserine and 8 µg/mL cefoxitin (Oxoid) (BHIS CC).
Strains were incubated overnight at 37 ◦C in an anaerobic workstation (Don Whitley
Scientific, Bingley, UK) with an atmosphere of CO2 (10%), H2 (10%) and N2 (80%).
2.2. C. difficile Spore Preparation
BHIS broth was inoculated with a loop of colonies from an overnight BHIS CC agar
culture and incubated anaerobically at 37 ◦C for 14–18 h. The culture was diluted 1:5
in BHIS broth and 100 µL were plated onto 5 BHIS plates. After a 5-day incubation,
culture from all plates were scraped and re-suspended in 1 mL PBS. The suspension was
heat shocked at 60 ◦C for 30 min to kill vegetative cells then centrifuged. The supernatant
was discarded, and the pellet washed in 1 mL sterile H2O, centrifuged and the washes
repeated 3 more times. The final pellet was re-suspended in 1 mL sterile H2O and stored at
−80 ◦C. In order to quantify spores, 10−1 to 10−8 dilutions of stocks in PBS were plated
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onto BHIS CC containing 10 µg/mL sodium taurocholate and the vegetative cells that form
colony forming units (CFU)s from germinated spores enumerated the next day.
2.3. Molecular Manipulations
Plasmid DNA was prepared using the Monarch® Plasmid Miniprep Kit according to
the manufacturer’s instructions (NEB). Enzymes for DNA manipulations included restric-
tion endonucleases (NEB), T4 DNA ligase (NEB) and Calf Intestinal Alkaline Phosphatase
(Invitrogen™, Thermo Fisher Scientific, Loughborough, UK). Gene cleaning was performed
using the Monarch® PCR & DNA Cleanup Kit (NEB) following the manufacturer’s instruc-
tions. DNA polymerase used for PCRs was Q5® High-Fidelity DNA Polymerase (NEB) for
cloning purposes or Taq DNA polymerase (NEB) for verification of constructs or for colony
PCR. PCRs were performed in an Eppendorf® Mastercycler® (Stevenage, UK)). Reaction
mixtures were typically subjected to initial denaturation at 94 ◦C for 5 min followed by
35 cycles: Denaturation at 94 ◦C for 30 s, annealing at the appropriate temperature for
the primers for 30 s and extension at 72 ◦C for 30 s to 1 min depending on the length of
amplicon, and a final extension cycle at 72 ◦C for 5 min. The amplified DNA was visualised
by electrophoresis with 1% w/v agarose gels.
2.4. Engineering of Antigen Expression Constructs
The Intein Mediated Purification with an Affinity Chitin-binding Tag-Two Intein
(IMPACT-TWIN) system was used (NEB), specifically the pTWIN1 vector, which was
modified to incorporate a second affinity tag, 10x Histidine. Primers pET52bFor: 5′-
GGTGGTGGATCCGCTGGTGCCACGCGGT-3′ and pET52bRev: 5′-GGTGGTGCTCAGCT
TAGTGGTGGTGATGGTG-3′ were used to PCR-amplify the region incorporating the His
tag from pET-52b (+) (Novagen, Merck Group, Feltham, UK) and the amplicon ligated
into BamHI-BlpI sites of pTWIN1. The construct was confirmed by sequencing using
primers Ssp intein for: 5′-ACTGGGACTCCATCGTTTCT-3′ and His check seq Rev: 5′-
ATAGTTCCTCCTTTCAGC-3′.
The nucleotide sequence of CD0873 and of the terminal fragment of the RBD of
TcdB (AA 1852-2366) of C. difficile strain 630 were codon-optimised for E. coli. Addi-
tionally, the single cysteine found three-quarters of the way into the coding sequence of
both antigens was substituted with alanine. This was to prevent any disulphide bond
forming between this cysteine and the free cysteine at the N-terminus, which could
impact on the tertiary structure of the recombinant protein potentially altering impor-
tant immunological epitopes. The gene strings were chemically synthesised (Life Tech-
nologies, Thermo Fisher Scientific) and used as template for PCR with primers 0873
For: 5′-GGTGGTTGCTCTTCCAACTGTAGCCAAGGTGGTGATAG-3′ and 0873 Rev: 5′-
GGTGGTTGCTCTTCCAACTGTAGCCAAGGTGGTGATAG-3′ and TcdB-RBDFor: 5′-GGT
GGTTGCTCTTCCAACTGTATTACCGGT-3′ and TcdB-RBDRev: 5′-GGTGGTGGATCCTCG
CTAATAACCAG-3′ respectively. The PCR products were digested with SapI, PstI or SapI,
BamHI and ligated to the SapI-PstI or SapI-BamHI sites of pTWIN1-His and ligation mixtures
used to transform NEB® 5-alpha cells. Clones were confirmed by sequencing as above then
transformed into T7 Express cells.
2.5. Expression and Purification of Recombinant Antigens by Immobilised Metal Affinity
Chromatography (IMAC)
First, 1 L E. coli broth cultures A600 0.6–0.7 were induced by adding isopropyl β-D-
1-thiogalactopyranoside (IPTG) to a final concentration of 0.3 mM with shaking at room
temperature overnight. Cells were harvested by centrifugation. The cell pellet was resus-
pended in ice-cold binding buffer (20 mM Tris-HCl, 1 M NaCl, 40 mM imidazole, pH 7.4),
sonicated using the Fisherbrand™ Q500 Sonicator then centrifuged. The supernatant
(cytosolic/soluble fraction) was harvested, and the pellet (insoluble fraction) re-suspended
in binding buffer and the fractions analysed by sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE) (2.9).
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The soluble fraction was passed through a pre-charged Ni2+ PD-10 column (GE, Health-
care Life Sciences, Amersham, UK) containing Blue Sepharose 6 Fast Flow resin (GE, Health-
care). The flow-through was collected then the beads were washed with binding buffer to
remove unbound proteins. The target protein was eluted with increasing concentrations
of imidazole (50 mM, 100 mM, 250 mM and 500 mM) in elution buffer (0.1 M Tris-HCl
and 2.5 M NaCl). All eluates were checked by SDS-PAGE (2.9) and those containing pure
protein combined for dialysis in PBS at 4 ◦C overnight.
CDTcdB-RBD localised in the insoluble fraction and thus additional on-column solu-
bilisation was required. The pellet was re-suspended in breaking buffer (binding buffer
containing 500 mM NaCl and 6M guanidine HCl) then centrifuged. The supernatant was
loaded onto Ni2+ columns equilibrated in breaking buffer then flushed sequentially with
binding buffer containing 6 M urea, 4 M urea, 2 M urea, finally 1 mM reduced glutathione
and 0.1 mM oxidised glutathione. The solubilised protein was then passed through a Ni2+
column and the protein purified as above.
All protein suspensions were standardised to 1 mg/mL in PBS and aliquoted in
1 mL volumes to which 1 mg of trehalose (cryoprotectant) was added as an excipient.
Each aliquot was lyophilised by snap freezing in liquid nitrogen then freeze-dried overnight
in a FreeZone® Benchtop Freeze dryer 2.5 L (Labconco, Kansas City, MO, USA). Each pow-
dered aliquot was packed separately into gelatin capsules, size 9 (Torpac Fairfield, NJ, USA)
using the funnel, tamper and stand provided by the manufacturer.
2.6. Dissolution Assay to Optimise Enteric Coating
Optimisation of capsule coating was conducted by testing maximum resistance to
dissolution in simulated gastric fluid, DILUT-IT™ (J.T.Baker, Avantor, Allentown, PA, USA)
pH 1.2, and maximum susceptibility to dissolution in simulated intestinal fluid, PBS pH 6.7.
Capsules were first packed with 22 mg of powdered Bromophenol Blue and glucose
(Sigma, Merck Group, Feltham, UK) 1:2.5. The polymer solution described by Staelens
et al., (2016) [47] was used; 12.5% EUDRAGIT L100 (Evonik Industries, Essen, Germany) in
isopropanol with Triethyl citrate (TEC) (10% w/v) added as a plasticizer and the addition of
3% H2O (w/w) tested. One versus two coats were compared. In duplicate, capsules were
individually placed in 5 mL of simulated gastric fluid and absorbance measurements taken
over 5 h at 450 nm. The capsules were then transferred to 5 mL of simulated intestinal fluid
and absorbance measurements were taken over 5 h at 590 nm.
2.7. Live CT Imaging to Track Location of Capsule Dissolution
Four capsules were packed with 25 mg BaSO4 and dip coated once in the optimised
polymer solution: 12.5% EUDRAGIT L100 containing 10% TEC and 3% H2O. Four female
Golden Syrian hamsters aged 12–16 weeks, weighing approximately 150 g were purchased
from Janvier Labs (Le Genest-Saint-Isle, France), housed in individually vented cages (IVCs)
then a week later given a single capsule orally via a Luer lock dosing applicator. For the
acquisition of in vivo Computer Tomography (CT) scans, hamsters were anesthetised with
1.5% Isoflurane in 100% oxygen (AB) prior to each scanning time point; 1.5 h, 3 h and 5 h
post administration then allowed to recover completely from each anaesthetic using O2.
After the final recovery, animals were euthanised (2.16).
In vivo acquisition of CT scans was taken on a BioScan SPECT/CT and reconstructed
on Nucline software (version 2.3, Mediso, Budapest, Hungary). Scans were acquired using
the following scan parameters; 45 kVp-X-ray source voltage at 35 ms exposure time per
projection resulting in a total scan time of 15 min. Reconstructed 3D 22 µm3 isotropic
voxel data sets were generated, and images were processed using Vivoquant software
(version 4.1, Invicro, a Konica Minolta Company, Boston, MA, USA).
2.8. In Vivo Immunogenicity Study
Female Golden Syrian hamsters aged 12–16 weeks, weighing approximately 150 g
were purchased from Janvier Labs and housed in IVCs. Hamsters were randomly divided
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into 4 groups: Experimental group given capsules containing recombinant CD0873 in
excipient (n = 4), experimental group given capsules containing recombinant CDTcdB-RBD
in excipient (n = 4), non-immunised i.e., naïve negative control group (n = 2) and a group
given capsules containing excipient only (n = 2). The purpose of this latter group was
to check if the capsule or excipient contributed towards any immunogenicity detected
in experimental groups. Oral dosing with capsules was performed on days 1, 15 and 30.
Hamsters were euthanised 14 days post final immunisation (2.16). Blood was collected by
cardiac puncture, left to clot overnight at 4 ◦C and serum harvested after centrifugation.
A section of the ileum was fixed in 10% (v/v) neutral buffered formalin (NBF) (Sigma) for
histological analysis (2.15). The remainder of the small intestine was placed in 5 mL PBS
containing SIGMAFAST™ protease inhibitors (Sigma ), flushed through twice with 1 mL
of this suspension then the supernatant collected after centrifugation. Serum and intestinal
fluid were filter-sterilised and stored at −80 ◦C.
2.9. SDS-PAGE and Western Immunoblotting and Whole Cell Immuno-Dot Blotting
Procedures were performed as described previously [48] with 5% dry-milk (w/v)
(Sigma) in Tris buffered saline containing 0.01% Tween (v/v) (TBST) for blocking. All an-
tibodies were diluted in 1% w/v dry-milk in TBST and TBST used for washes. Samples
(soluble and insoluble fractions of cell lysates, eluates, purified recombinant protein or
intestinal fluid from hamsters) were added to 2X Laemmli sample buffer and fractionated
by 10% (w/v) SDS-PAGE. Transfer to PVDF membranes was conducted using the Trans-Blot
Turbo Transfer System (Bio-Rad, California, USA). Primary antibodies used were rabbit anti-
His tag antibody (1:1000) from Cell Signaling Technologies, CST(Danvers, MA, USA) rabbit
anti-CD0873 antibody [39] (1:5000) and mouse anti-TcdB antibody (1:1000) (The Native Anti-
gen Company, Oxford, UK) to confirm antigens. Rabbit-anti-hamster secondary antibody
was used to detect the heavy chain (H) of IgA (Brookwood Biomedical, Jemison, AL, USA).
Briefly, IgA (H) antibody was purified from rabbit anti-hamster IgM, IgG, IgA (H) by cross
absorption against hamster IgG and IgM (Brookwood Biomedical) and used at 1:1000 to
detect vaccine-induced sIgA in intestinal fluid. Secondary antibodies used were anti-rabbit
IgG horseradish peroxidase (HRP) (1:1000) (CST) and anti-mouse IgG HRP (1:1000) (CST).
Protein bands were detected using 3,3′, 5,5′-Tetramethylbenzidine (TMB) substrate (Sigma)
and visualised using the Gel Doc™ XR system (Bio-Rad, CA, USA). Immuno-dot blots
were performed by spotting whole cell suspensions of C. difficile onto Nitrocellulose [48]
then conducting the Western immunoblotting procedure described.
2.10. Indirect ELISA to Assess IgG Levels in Serum
Ninety-six–well Nunc MaxiSorp™ plates were coated with 100 µL purified recombi-
nant proteins; CD0873 and CDTcdB-RBD at a concentration of 2.5 µg/mL in 0.2 M sodium
bicarbonate, pH 9.4 and the proteins left to adsorb onto the wells overnight at 4 ◦C. All wash
stages consisted of 5 washes with 200 µL PBS containing 0.01% Tween (PBST). Wells were
first blocked with 200 µL of 5% dry-milk (Sigma) in PBST for 2 h at room temperature,
washed then incubated over night at 4 ◦C after addition of 100 µL serum diluted 1:10
in PBST, in triplicate. Wells were washed then incubated for 2 h at room temperature
in 100 µL goat anti-hamster IgG highly cross adsorbed-Biotin antibody (Sigma) diluted
1:20,000 in PBST, washed again then incubated for 2 h in Streptavidin-HRP (R&D Systems,
Minneapolis, MN, USA) diluted 1:200 in PBST. A650 was measured after addition of 100 µL
TMB substrate (Sigma) for 15 min using the CLARIOstarPlus (BMG Labtech) Plate Reader.
2.11. Toxin Neutralization Assay
VERO cells were seeded at 1 × 104 per well in a 96-well plate in 50 µL phenol red-
free DMEM (Gibco™-ThermoFisher Scientific) supplemented with 4.5 g/L D-glucose,
584 mg/L L-glutamine, 25 mM HEPES, penicillin/streptomycin and 10% v/v fetal bovine
serum (FBS) (Sigma) and incubated for 18–20 h at 37 ◦C in 5% CO2. Serum and intestinal
fluid were serially diluted 2-fold (serum, 1:4 to 1:512 and intestinal fluid 1:128) in serum-
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free, phenol red-free DMEM and mixed with either an equal volume of TcdA at 200 ng/mL
or TcdB at 1 ng/mL for 1 h at 37 ◦C. Neat and serial dilutions of serum or intestinal fluid-
toxin mixtures were added to VERO cells in triplicates to give a total well volume of 100 µL
and plates were incubated for 22 h at 37 ◦C. The final concentration of TcdA and TcdB was
50 ng/mL and 0.25 ng/mL respectively. Toxin neutralization was assessed by MTT assay.
Briefly, all medium was removed from cells and 50 µL DMEM containing 0.5 mg/mL
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to each
well and incubated at 37 ◦C for 4 h. After removal of MTT solution, 75 µL DMSO was
added to cells, and after 10 min the absorbance was read at 570 nm.
2.12. Adherence Blocking Assay
Caco-2 cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM) (Gibco™-
ThermoFisher Scientific) supplemented with 4.5 g/L D-glucose, 584 mg/L L-glutamine,
25 mM HEPES, 10% v/v FBS and penicillin/streptomycin in a humidified 5% CO2 at-
mosphere at 37 ◦C. Cells were seeded at 5 × 104 cells per well in 24-well tissue culture
plates (Corning). Monolayers were used 14 days after seeding with medium changed every
2–3 days. The culture medium was further changed 24 h prior to conducting the assay.
The inoculum was prepared by standardising the optical density (OD) of a 10 mL overnight
broth culture of C. difficile strain 630 to A600 0.6, centrifuging and washing the cells with
PBS and re-suspending the pellet in non-supplemented DMEM. Caco-2 monolayers were
infected at a multiplicity of infection (MOI) of 1:5 and 1:20 in triplicate. To confirm the MOIs,
10−1 to 10−7 dilutions of the cell suspension in PBS were plated on BHIS CC for enumera-
tion of CFUs. The adherence assay was performed under anaerobic conditions at 37 ◦C.
50 µL of serum or intestinal fluid diluted 1:5 and 1:2 respectively, in non-supplemented
DMEM were added to 50 µL of the bacterial cell suspension and incubated for 1 h. This mix-
ture was then added to Caco-2 cells in triplicate following removal of the medium in the
wells. After 2 h of incubation, non-adherent bacteria were removed by pipetting and adher-
ent bacteria harvested as follows. Caco-2 cells were washed 3 times with PBS, incubated
in 200 µL 1X trypsin-EDTA to detach them from the wells then re-suspended in 300 µL
supplemented DMEM. 10−1 to 10−3 dilutions of cells in PBS were plated on BHIS CC plates
and CFU enumerated the following day.
2.13. In Vivo Challenge Study
Female Golden Syrian hamsters aged 12–16 weeks, weighing approximately 150 g,
were purchased from Janvier Labs and housed in IVCs. Hamsters were randomly di-
vided into 3 groups: Naïve negative control group (n = 2), group immunised orally with
capsules containing recombinant CD0873 in excipient (n = 4) and a group given toxoids
(mock Sanofi Pasteur vaccine) (n = 2). The toxoid vaccine consisted of formalin-inactivated
TcdA and formalin-inactivated TcdB (Native Antigen Company, Oxford, UK) at 5 µg/dose
resuspended in an alum adjuvant in PBS [49]. This group was given an i.m. injection after
anaesthesia with Isoflurane (AB) on the same days as the experimental group that was
immunised orally.
Two weeks after the final immunisation (2.8), hamsters were orally gavaged with
100 µL clindamycin (30 mg/kg) to disrupt their gut microbiota then challenged 5 days
later with 103 spores of strain R20291ermB in 100 µL of PBS. Animals were monitored
several times daily for symptoms of CDI. In addition to monitoring weight (with a loss
of 20% between consecutive checks or 10% decrease at 2 consecutive checks resulting
in euthanasia), other parameters scored were wet tail or loose faeces, hunched posture,
piloerection and reduced activity and reduced response to stimuli. Scores of 0–3 were given
for each parameter (0 being no change and 3 being a major change) and animals euthanised
once CDI symptoms reached a threshold score of 15 [50] or once the experimental endpoint
was reached (2 weeks post infection). The bacterial load was monitored throughout the
study by enumerating spores shed in faeces (2.14) and the histopathology of the cecum
scored at the endpoint (2.15).
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2.14. Monitoring the Burden of C. difficile
Bacterial burden over time was monitored by enumerating the number of spores shed
in faeces, which are released by sporulating vegetative cells (one spore per vegetative cell).
Unlike vegetative cells that die upon exposure to O2 in the air, spores within faeces survive.
By plating faecal homogenates on BHIS CC containing sodium taurocholate (2.2), the veg-
etative cells that form CFUs from germinated spores can be enumerated the next day.
One millilitre of PBS was added to 100 mg of faecal pellet in a 2 mL Precellys® CK28
tube and homogenised using the Precellys® 24 Tissue Homogenizer (Bertin Instruments,
Montigny-le-Bretonneux, France). Suspensions were then centrifuged and the supernatant
containing spores harvested and stored at−80 ◦C. Serial dilutions were spotted in triplicate
onto plates as described above and CFU enumerated. Confirmation of colonisation with the
infecting strain, R20291ermB, was obtained by colony PCR with primers Cdi-630-pyrD-sF1
and ermB-HindII-R and the sequence of amplicons verified using the same primers [46].
2.15. Histopathological Assessment of Cecum
Intestinal sections were fixed in 10% NBF, processed overnight on a 14 h programme
in a TP1020 Automatic Benchtop Tissue Processor (Leica Biosystems, Newcastle, UK),
paraffin embedded in a Histostar Embedding Workstation (Thermo Fisher Scientific) and
sectioned at 5 µm, mounted on glass slides and Hematoxylin and Eosin (H&E) stained
(Leica ST 5020). Blinded analysis was conducted by an experienced pathologist using
an established scoring system [51]. Sections were assessed for oedema (0–3), neutrophil
infiltration (0–3) and epithelial tissue damage (0–3) with 0, normal and 3, severe.
2.16. Ethics Statement
Animal studies were devised usingthe Experimental Design Assistant (EDA) online
tool [52] and conducted in strict accordance with the requirements of the Animals Scientific
Procedure Act 1986. Prior approval for these procedures was granted by the University of
Nottingham Animal Welfare and Ethical Review Body and by the UK Home Office under
project license PPL P4712E8BB. Animals were euthanised by CO2 inhalation followed by
cervical dislocation to minimize suffering.
2.17. Statistical Analysis
The non-normally distributed data from this study were analysed as follows. For the
immunogenicity data: Antibody titre and adherence blocking, a non-parametric Mann–
Whitney U test was conducted. For clinical outcome following immunisation and challenge,
data for time to endpoint, weight, bacterial load and histopathology were analysed by a
non-parametric Mann–Whitney U test. For animal survival data, a Kaplan–Meier survival
analysis was conducted using a log-rank (Mantel–Cox) test. All statistical tests were
performed using GraphPad version 7 (San Diego, CA, USA) and p values of less than 0.05
were considered to indicate statistical significance.
3. Results
3.1. Purification of RecombInant Protein Antigens with an N-Terminal Cysteine by Novel Double
Affinity Tagging
The colonisation factor CD0873 is a conserved, surface-exposed lipoprotein [39].
Lipoprotein precursors harbour an N-terminal signal peptide ending in a lipobox with a ter-
minal cysteine. Following lipidation of this cysteine, cleavage of the signal peptide occurs
at the residue immediately before this such that the acylated cysteine forms the new N-
terminus. The signal peptide of CD0873 (strain 630) is MINKKRLASLILAGALSISMLTGC
as predicted by lipoprotein prediction programmes (LipoP 1.0, SignalP-5.0 and DOLOP).
In order to obtain the cleaved version of CD0873, the form that would be expressed
on vegetative cells, the IMPACT-TWIN system was used as it enables purification of re-
combinant proteins possessing an N-terminal cysteine. This is achieved by N-terminal
fusion of the target protein to an intein bearing a chitin-binding domain (CBD). The in-
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ducible self-cleavage activity of the intein separates the target protein from the affinity tag.
For consistency, we used the same system to express and purify the terminal fragment
of TcdB.
However, due to excessive self-cleavage without induction, prior to purification, the
target protein could not be trapped by chitin beads and was lost in the flow-through.
By incorporating a His tag in the pTWIN1 vector for C-terminal tagging, Ni2+ columns
could be used instead of chitin columns to trap the recombinant protein now bearing the
N-terminal cysteine (Figure 1).
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Figure 1. Schematic diagram of pTWIN1-His expression system. The expression vector pTWIN1
(NEB) was modified by the inclusion of a Hig tag for C-terminal tagging. This prevented loss of
the target protein due to excessive natural self-cleavage of the N-terminal intein tag bearing the
chitin-binding domain (CBD) by trapping the target protein with a Ni2+ column by Immobilised
Metal Affinity Chromatography (IMAC).
Briefly, the region incorporating the thrombin cleavage site and the His tag in pET52b
(+) was cloned into pTWIN1 to create pTWIN1-His and this new vector was used to
produce recombinant CD0873 and CDTcdB-RBD. The nucleotide sequence of both antigens
was taken from C. difficile strain 630 (NCBI), codon-optimised for E. coli and chemically
synthesised before cloning into pTWIN1-His.
Following induction of protein expression and affinity purification, SDS-PAGE re-
vealed a single band of expected molecular weight for each antigen; 36 kDa for CD0873
and 61 kDa for CDTcdB-RBD (Figure 2A,B). Confirmation of the proteins was obtained by
Western immunoblotting, probing with anti-His tag antibody, anti-CD0873 antibody or
anti-TcdB antibody and the bands detected with HRP-conjugated secondary antibodies and
TMB substrate (Figure 2C). Final dialysed protein suspensions were diluted to 1 mg/mL
in PBS, aliquoted into 1 mL volumes and cryoprotectant trehalose added as an excipient.
Each aliquot was lyophilised then packed into separate Torpac gelatin capsules and stored
at room temperature until required.
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3.2. Single Dip Coating of Gelatin Capsules with EUDRAGIT L100 Mixed with TEC and Water Is
Optimal for Targeted Release within the Small Intestine
In order to establish the most appropriate enteric coating to resist dissolution in the
acidic environment of the stomach but allow dissolution at the higher pH of the intestine for
targeted delivery of the encapsulated protein to the small intestine, 12.5% (w/v) EUDRAGIT
L100 was dissolved in isopropanol and mixed with 10% TEC [47]. The addition of 3%
H2O (v/v) to enhance the plasticity of the polymer was tested. Capsules were first packed
with powdered Bromophenol Blue and glucose then dip-coated either once or twice for
comparison. Capsule dissolution was monitored over 5 h in simulated gastric fluid, pH 1.2
then over 5 h in simulated intestinal fluid, pH 6.7 (Figure 3A–D). Capsules dip coated
once in L100 mixed with 10% TEC and 3% H2O resisted dissolution at pH 1.2 the greatest
(Figure 3C) and subsequently dissolved the fastest at pH 6.7 (Figure 3D). For all subsequent
in vivo studies, capsules were dip-coated once in this formulation.
To investigate targeted delivery to the small intestine in vivo, capsules were packed
with BaS04, dip-coated once in the optimised polymer mixture then a single capsule was
given orally to hamsters (n = 4). CT of the same capsule and animal was performed to track
localisation of the capsule over time. The BaS04-containing capsule was clearly visible as an
intact capsule in the stomach 1.5 h after administration (Figure 3E). Partial degradation of
the capsule and release of mainly non-dissolved BaS04 in the small intestine was observed
at 3 h. The capsule had completely disintegrated and disappeared at 5 h and the BaS04
dispersed and fully solubilised in the intestinal fluid (Figure 3E). The in vivo findings
corroborate our in vitro results that the capsule coated with L100 mixed with 10% w/v TEC
and 3% H2O resisted the low pH of the stomach and disintegrated at the higher pH of the
small intestine.
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3.3. Mucosal and Systemic Antibody Responses Are Detected in CD0873-Immunised Hamsters
The hamster model is widely recognised as a stringent and relevant model for the eval-
uation of novel therapies and vaccines against C. difficile [49]. Hamsters were dosed orally,
one capsule per dose, on days 1, 15, and 30 then euthanised two weeks later. One exper-
imental group was immunised with capsules containing 1 mg of lyophilised CD0873 in
trehlaose and another group with capsules containing 1 mg of lyophilised CDTcdB-RBD
in trehlaose. Negative control groups included naive hamsters or hamsters given capsule
containing excipient, trehalose only. At the experimental endpoint, a section of the ileum
(the mucosal inductive site) was taken for histological analysis, and serum and intestinal
fluid were harvested. Histological analysis revealed no inflammation of the ileum in any of
the hamsters indicating good safety of all formulations).
To investigate the prevalence of sIgA in the small intestine, diluted intestinal fluid
of each hamster was probed by Western immunoblotting with rabbit-anti-hamster IgA
(H) antibody and detected by anti-rabbit IgG HRP. A strong immuno-reactive band was
observed for each of the CD0873-immunised hamsters corresponding to the molecular
weight expected for the H chain of hamster IgA, reported previously to run between
51 kDa and 86 kDa [53] (Figure 4A). Given the very little fluid that can be extracted
from the thin tubing of the small intestine of hamsters, a considerable volume of PBS
(5 mL) was used to flush out the antibodies and this was further diluted 1:2 in sample
buffer for fractionation. Despite being heavily diluted, the intense band observed for each
immunised animal corresponding to the size of the H chain suggests a high titre of sIgA in
the small intestine. No band was detected for any of the negative control group animals
(Figure 4A). Likewise, there was no detection of sIgA in intestinal fluid of CDTcdB-RBD-
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immunised animals). As with naive animals, since no background level of antibody was
detected for animals given capsules containing excipient only, this group was excluded
from further assays.
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Figure 4. Immune responses in hamsters immunised orally with CD0873. Intestinal fluid and
serum were harvested from hamsters vaccinated with recombinant CD0873 and from hamsters given
capsule containing excipient only as well as from naïve hamsters and tested for the presence of sIgA
and IgG, respectively. Intestinal fluid was extracted by flushing the small intestine with 5 mL of
PBS containing protease inhibitors and serum was taken by cardiac puncture at the experimental
endpoint. Intestinal fluid was further diluted 1:2 in sample buffer and serum was diluted 1:10.
(A) Intestinal fluid (5 µL) from each hamster was fractionated by SDS-PAGE along with Colour
Prestained Protein standard (NEB) and transferred to a PVDF membrane. The membrane was probed
with rabbit anti-hamster IgA antibody (1:1000) and bands detected with anti-rabbit IgG HRP (1:1000)
and TMB substrate. (B) Serum was pooled separately for the CD0873-vaccinated group and naïve
group and tested for IgG by indirect ELISA. Goat anti-hamster IgG highly cross adsorbed-Biotin
antibody (1:20,000) and Streptavidin-HRP (1:200) were used for detection. Data were obtained from
two independent experiments, each with three technical replicates. Error bars represent standard
error of the mean (SEM). A non-parametric Mann-Whitney U test was performed to compare groups.
Statistical difference p value; (***) p < 0.001.
In order to test whether immunised hamsters further generated a systemic immune re-
sponse, pooled sera from immunised or naive hamsters were compared by indirect ELISA.
Wells were first coated in recombinant CD0873 or CDTcdB-RBD then incubated in di-
luted serum. Biotin-labelled goat anti-hamster IgG was added and Streptavidin-HRP used
for detection. A significantly higher titre of CD0873-specific IgG was detected in CD0873-
immunised sera compared to naive animals p = 0.0001 (Figure 4B). Conversely, a non-
significant difference in CDTcdB-RBD-specific IgG titre was observed between CDTcdB-
RBD immunised and naive sera, p = 0.1797 (Figure A1). Toxin neutralisation assays with
Vero cells were performed with sera from CDTcdB-RBD-immunised hamsters, but no neu-
tralisation was observed. We conclude that only recombinant CD0873 was immunogenic
and successfully stimulated both mucosal and systemic antibody responses.
3.4. Intestinal Fluid and Serum of CD0873-Immunised Hamsters Inhibits the Adherence of
C. difficile to Caco-2 Cells
To test if CD0873-induced antibodies in the intestinal fluid and in serum function in
inhibiting colonisation of C. difficile to epithelial cells, Caco-2 cells were infected with C. dif-
ficile strain 630 pre-incubated with pooled intestinal fluid diluted 1:2 or pooled sera diluted
1:5. Two hours post infection, cells were washed and detached from wells with Trypsin
then serial dilutions plated and CFUs enumerated. There was a significant reduction in
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the number of adhered cells of C. difficile when pre-incubated with intestinal fluid from
immunised animals compared to naive animals, p = 0.0320 (Figure 5A). An even greater
reduction in adherence was observed when C. difficile was pre-incubated with sera from
immunised animals, p = 0.0001 (Figure 5B). Our findings suggest that CD0873-induced an-
tibodies generated locally in the gut and systemically function in reducing the colonisation
of C. difficile to epithelial cells.
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vaccine) for comparison [49]. Hamsters were given clindamycin by oral gavage to disturb 
their gut microbiota then infected five days later by oral gavage with 103 spores of a hy-
pervirulent strain of C. difficile. Specifically, R20291ermB was used since ermB confers a 
Figure 5. Adherence of Clostridioides difficile to Caco-2 cells is reduced by CD0873 antibodies. Adherence of C. difficile to
Caco-2 monolayers after the bacterial cells wer pre-incubated with (A) int stinal fluid diluted 1:2 and (B) sera diluted 1:5
from CD0873 orally immunised hamsters or from naïve hamst rs. C ll-binding was m asured by enumerating CFU from
washed Caco-2 cells. The values are mean numbers of adherent bacteria per 100 Caco-2 cells. The assay was performed
in triplicate. Error bars represent standard error of the mean (SEM). A non-parametric Mann–Whitney U test was performed
to compare groups. Statistical difference p-value; (*) p < 0.05 and (***) p < 0.001.
3.5. Hamsters Immunised Orally with CD0873 Are Partially Protected from C. difficile Infection
Hamsters were immunised orally as before with CD0873 and compared to the naïve group.
Another group was given formalin-inactivated toxoids i.m. (mock Sanofi Pasteur vaccine)
for comparison [49]. Hamsters were given clindamycin by oral gavage to disturb their
gut microbiota then infected five days later by oral gavage with 103 spores of a hypervir-
ulent strain of C. difficile. Specifically, R20291ermB was used since ermB confers a degree
of resistance to clindamycin (in addition to erythromycin) thus avoiding killing of the
inoculum by residual antibiotic at the time of infection [50]. Another benefit of using
R20291ermB is to facilitate confirmation of the infecting strain by PCR detection of ermB
in fecal homogenates. Surface expression of CD0873 on cells of strain R20291ermB was
verified by whole cell immuno-dot blotting with anti-CD0873 antibody [39] prior to use
in the hamster model (Figure A2). After infection, animals were monitored frequently
for signs of CDI. Changes in body condition were scored and animals euthanised once a
threshold score was reached as a result of fulminant CDI [54]. The experimental endpoint
was two weeks post infection.
The mean time to endpoint for the CD0873 orally immunised group was 80% greater
than the naive group. One of the four CD0873-vaccinated hamsters displayed no symptoms
of infection (Figure 6A,B). This hamster showed a normal, non-enlarged cecum post-
mortem. Another of the CD0873-vaccinated animals showed only mild symptoms but was
euthanised 96 h post challenge (Figure 6A,B). Post-mortem confirmed only minor swelling
of the cecum. All other animals succumbed to disease within 70 h of being challenged
and demonstrated highly enlarged ceca and loose faeces (Figure 6A,B). All hamsters
progressively lost weight up to the endpoint except for the CD0873-vaccinated hamster
that did not develop any clinical symptoms (survivor) (Figure 6C). After initially losing
up to 10% of its initial weight over four days post challenge, it regained its weight within
the next four days (Figure 6C). Its weight profile inversely correlated with bacterial load
with CFU counts peaking at four days post challenge and diminishing after this with no
shedding observed beyond day 10 (Figure 6D). Hamsters immunised i.m. with toxoids
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showed no protection.Confirmation of the presence of the infecting strain in all challenged
animals was acquired by PCR detection of ermB from faecal homogenates (Figure A3) and
verified by sequencing.
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a Kaplan–Meier survival analysis was conducted using a log-rank (Mantel-Cox) test. For B, C and D, a non-parametric
Mann–Whitney U test was used. Non-significance (p > 0.05) was reported for all data sets.
Although non-significance was determined for the vaccinated group, a trend in pro-
tection was clearly evident. The non-significance observed is likely reflective of the lack of
statistical power due to the small n values used. To investigate the condition of the cecum of
the fully protected hamster compared to that of naïve hamsters or hamsters given toxoids
that succumbed to infection, the ceca were compared for histopathological differences.
3.6. Histological Examination of the Cecum Shows Reduced Pathology in
CD0873-Immunised Hamsters
For each hamster, a small portion of the cecum was taken, fixed, embedded and sec-
tioned then mounted on slides and H&E stained. Sections were assessed for oedema (0–3),
neutrophil infiltration (0–3) and tissue damage (0–3) with 0, normal and 3, severe. Scores for
the 3 parameters were combined for each group. As expected non-significance was ob-
served (Figure A4), however the CD0873-immunised hamster that was protected from CDI
showed profoundly reduced pathology compared to naïve animals or animals given tox-
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oids. The submucosa layer remained thin, the epithelium was relatively preserved and
there were markedly fewer neutrophils (Figure 7B). Conversely, the toxoids-vaccinated and
naïve animals both showed extensive oedema, damaged epithelium and an abundance of
neutrophils in the Lamina Propria and submucosa (Figure 7A,C).Microorganisms 2020, 8, x FOR PEER REVIEW 17 of 24 
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is far less neutrophil infiltration than seen in the toxoids group or naïve group. Likewise, very little oedema is bserved
for the CD0873-vaccinated hamster and the epithelium appears relatively intact in contrast to the toxoids vaccinated and
naïve groups, which showed extensive oedema and damaged epithelium.
4. Discussion
Natural protection against extracellular mucosal pathogens requires primarily the
production of sIgA antibodies that prevent attachment of pathogens to the mucosa and
can furthermore neutralise the exotoxins [55,56]. Large complexes form of pathogens
bound by sIgA, which get entrapped by mucous and cleared. A secondary systemic
response often follows whereby serum IgG antibodies control mucosally invasive and
systemically invasive pathogens by directly activating complement-mediated killing and
by opsonophagocytosis [57].
Early studies investigating natural immune responses to CDI focused on testing sera
for these secondary systemic responses. It was found that high titres of TcdB-specific serum
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IgG correlated with recovery from CDI without relapse and similar observations were
reported for TcdA antibodies [58,59]. Conversely the inability to mount serum anti-toxin
antibodies was associated with increased risk of recurrent CDI [58,60]. Many preclinical
studies ensued whereby hamsters and mice were parenterally immunised with toxin-based
formulations to induce toxin-neutralising serum IgG antibodies and different degrees of
protection were reported [42,44,49,61–66]. However, results from human trials administer-
ing toxoid formulations parenterally have not supported the protective efficacies observed
in preclinical studies, with Sanofi Pasteur terminating their phase III trial in 2017.
Oral immunisation on the other hand is a far more effective route for directly stim-
ulating intestinal sIgA responses [67]. Licensed oral vaccines against polio, rotavirus,
Salmonella typhimurium and Vibrio cholera 01 consistently demonstrate sIgA, as well as
serum antibody and cellular immune responses, with strong protection against mucosal
infection [68].
To this end, a pilot study in hamsters was conducted to test two recombinant antigens:
Colonisation factor CD0873 and the terminal portion of TcdB, CDTcdB-RBD. Oral immu-
nisation with CD0873 resulted in a high titre of sIgA in intestinal fluid and IgG in serum
compared to naive animals, which significantly reduced the adherence of C. difficile to
Caco-2 cells. With evidence of a mucosal antibody response, as well as a systemic humoral
response against CD0873, we tested the protective efficacy of this antigen delivered orally.
For the challenge strain, we chose heterologous R20291ermB derived from hypervirulent
isolate R20291 () that is associated with severe disease, responsible for two outbreaks of
CDI in the UK [69].
The orally immunised CD0873 group was partially protected with a mean increase of
80% in time to endpoint compared to the naive group (Figure 6A,B). One of the vaccinated
hamsters was fully protected from CDI and displayed no symptoms other than up to
10% loss in weight, which was regained (Figure 6C). The weight profile of the survivor
inversely correlated with bacterial load with no viable C. difficile detectable from day 10
indicating complete pathogen clearance (Figure 6D). The cecum at the endpoint showed
marked reduced pathology compared to animals of both control groups that succumbed
to infection (Figure 7A). Another of the CD0873-immunised animals showed only mild
symptoms of CDI. This hamster may have also gone on to clear infection had it not been
culled (Figure 6B). Conversely, animals immunised parenterally with toxoids showed no
protection and remained fully colonised at levels indistinguishable from naïve animals
(Figure 6) consistent with previous observations by Hong et al. (2017) [70].
The findings suggest that CD0873-specific sIgA antibodies bind CD0873 and coat the
surface of vegetative cells of C. difficile which blocks their attachment to colonic epithe-
lial cells, as supported by our adherence blocking results with Caco-2 cells (Figure 5B).
In the survivor, we speculate the bacteria go on to multiply in the lumen instead and are
then readily shed (Figure 6D). Indeed, the bacterial load in faeces of the survivor at day 4
exceeded the highest load of all other animals that succumbed to infection. The healthy
body condition of the vaccinated hamster correlated with the lack of toxin-mediated dam-
age to the cecum. Our data suggests that bacterial coating by sIgA may not only prevent
toxins being brought into close proximity to epithelial cells by sterically hindering adhesion
of C. difficile to enterocytes but may block toxin secretion itself and sIgA may additionally
directly neutralise these toxins (Figure 7B). Furthermore, it appears that these vaccine-
induced antibodies were not only antitoxic (be it directly or indirectly) but also antibacterial
as seen by clearance of infection by day 10 (Figure 6D)
Mucosal sIgA is known for its ability to intercept infection by (a) preventing the
adhesion of pathogens to the mucosal epithelium and (b) directly neutralising entero-
toxins [56,71] or blocking their interaction with epithelial cells, as shown for cholera
toxins [72]. Interestingly, intestinal sIgA generated in response to oral administration of
the Dukoral vaccine, which contains recombinant cholera toxin B, is not only antitoxic but
antibacterial and confers protection against both cholera and Enterotoxigenic E. coli [73].
Moreover, there have been several studies demonstrating a direct association between
Microorganisms 2021, 9, 306 18 of 23
sIgA and enterotoxin TcdA of C. difficile. Firstly, Dallas and Rolfe (1998) reported that
sIgA in human milk binds to TcdA. These workers proposed that this protease-resistant
immunoglobulin naturally abundant in milk confers protection to breast-fed infants by
preventing TcdA from binding intestinal epithelial cells [74]. Indeed, infants typically show
high rates of colonisation with C. difficile but remain asymptomatic suggesting successful
toxin interception or neutralisation. Secondly, oral immunisation of hamsters with spores
of Bacillus subtilis engineered to express a repeat unit of the RBD of TcdA generated sIgA
and IgG both of which were able to neutralise TcdA and TcdB with 75% protection against
primary CDI and complete protection from re-challenge [75]. Crucially it was the mucosal
antibodies that were found to correlate with the protection observed [70,75].
In evaluating the protective efficacy data for CD0873, there are several important
points to note. Firstly, although a clear trend in protection was observed, non-significance
was found. This was not surprising given that this was a pilot study using small n values
Further studies with larger group sizes for statistical power are warranted. Secondly, vari-
ation was observed between hamsters, which is not uncommon and there are several
contributing factors that apply specifically to this study. Enteric capsules and polymers
available for rodents are less advanced than capsules used for humans with variation in
delivery to the small intestine inevitable. For oral vaccines, more than one dose is often
necessary to overcome tolerance (immunological unresponsiveness that can arise after oral
administration of an antigen) yet how many doses of the three successfully localised to
the small intestine is not known. Additionally, it is probable that the mode of challenge
i.e., the choice of strain and size of inoculum used overwhelmed the immune system.
Challenging with a lower number of spores that is more realistic of a natural infection may
reveal that CD0873 is more protective than observed in this study.
To conclude, in addition to the attractive immunological properties of CD0873, we show
that it can be successfully delivered in the form of lyophilised recombinant full-length
protein since it is highly soluble. The propensity for lyophilised antigens to readily recon-
stitute in vivo is essential for structural reformation of immunological epitopes. Moreover,
consistent detection of sIgA in every immunised animal in our immunogenicity study (3.3)
suggests CD0873 has good bioavailability. In contrast, CDTcdB-RBD from the initial purifi-
cation stage was insoluble and following lyophilisation, did not readily reconstitute in PBS.
Its insolubility may largely explain the lack of immunogenicity observed for this antigen.
To immunise successfully against CDI, our work highlights the importance of oral de-
livery in generating intestinal sIgA to block colonisation as well as intercept and potentially
neutralise the enterotoxins. In addition to CD0873, the inclusion of soluble immunogenic
domains of the toxins are likely to enhance toxin neutralisation and it would also be
beneficial to include an immunogenic domain of the binary toxin for further protection
against hypervirulent isolates. Additional practical benefits of an oral C. difficile vaccine
over injected vaccines are improved safety, easier manufacturing and administration with
greater compliance particularly amongst the elderly, a key target population.
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Figure A2. Immuno-dot blot of whole cells of Clostridioides difficile probed with rabbit anti-CD0873 
antibody [39] to confirm surface expression of CD0873 on the hypervirulent strain R20291ermB 
used for challenge studies. (A) Strain 630, with known CD0873 surface expression [39], was used 
as a positive control for comparison to strain R20291ermB. Cells from overnight plate cultures 
were resuspended in 100 µL PBS and 5 µL spotted onto Nitrocellulose in duplicate. (B) Recombi-
nant CD0873 was used as a positive control with 5 µL (2 ng/µL)) spotted in duplicate. The mem-
branes were blocked in 5% dried milk in TBST for 1 h then incubated with rabbit anti-CD08730 
antibody (1:5000) then in anti-rabbit IgG HRP (1:1000), with both antibodies diluted in 1% dried 
milk in TBST. Spots were detected by TMB substrate and visualised using the Gel Doc™ XR+ sys-
tem with the Image Lab software (Bio-Rad). 
Figure A1. Detection of IgG in serum by indirect ELISA from hamsters immunised with CDTcdB-RBD
and from naïve animals. Serum was pooled separately for the two groups and used at a 1:10 dilution.
Goat anti-hamster IgG (H + L) highly cross adsorbed-Biotin antibody (1:20,000) and Streptavidin-HRP
(1:200) were used for detection. Data were obtained from 2 independent experiments, each with
3 technical replicates. Error bars represent standard error of the mean (SEM). A non-parametric
Mann-Whitney U test was performed to compare groups and non- significance ( s) found (p > 0.05).
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Figure A2. I muno-dot bl t of whole cells of Clostridioides difficile probed with rabbit anti-CD0873
antibody [39] to confirm surface expression of CD0873 on the hypervirulent strain R20291ermB used
for challenge studies. (A) Strain 630, ith rf ce expre sion [39], was used as
a positive control for co parison to strain R20291ermB. Cells from overnight plate cultures were
resuspended in 100 µL PBS and 5 µL spotted onto Nitrocellulose in duplicate. (B) Recombinant
CD0873 was used as a positive control with 5 µL (2 ng/µL)) spotted in duplicate. The membranes
were blocked in 5% dried milk in TBST for 1 h then incubated with rabbit anti-CD08730 antibody
(1:5000) then in anti-rabbit IgG HRP (1:1000), with both antibodies ilu ed in 1% dried milk in TBST.
Spots were detect d by TMB substrate and visualised using the Gel Doc™ XR+ system with the
Image Lab software (Bio-Rad).
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